DGX vs NTRA
DGX: Quest Diagnostics is the largest clinical laboratory testing company in the U.S., providing diagnostic insights to healthcare providers, employers, and consumers to improve health outcomes and enable value-based care. NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health.
Side-by-side fundamentals
| Metric | DGX | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $209.83 | $264.22 | |
| Market cap as of 2026-07-23 | $23.0B | $37.9B | |
| P/E as of 2026-07-23 | 22.47 | n/a | |
| PEG as of 2026-07-23 | 2.41 | -13.63 | NTRA lower |
| Net margin as of 2026-07-23 | +9.1% | -9.1% | DGX higher |
| Gross margin as of 2026-07-23 | +33.3% | +65.1% | NTRA higher |
| Operating margin as of 2026-07-23 | +14.3% | -13.0% | DGX higher |
| ROE as of 2026-07-23 | +14.1% | -15.1% | DGX higher |
| ROA as of 2026-07-23 | +6.3% | -10.5% | DGX higher |
| Debt / equity as of 2026-07-23 | 0.77 | 0.05 | NTRA lower |
| Revenue growth (YoY) as of 2026-07-23 | +11.0% | +36.6% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +3.7% | +41.1% | NTRA higher |
| Dividend yield as of 2026-07-23 | +1.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.56 | 1.54 | |
| 1-year return as of 2026-07-22 close | +24.3% | +88.8% | NTRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.